Trial Profile
A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With DLI for the Treatment of AML or MDS Relapsing After Allogeneic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 12 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 12 Sep 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 24 Mar 2023 Planned End Date changed from 3 Aug 2022 to 31 Dec 2023.